COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Upper GI Symptoms In Patients Receiving Acetylsalicylic Acid/NSAIDs - NSAIDs Wave 2 (NSAIDS II)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00691743
Recruitment Status : Completed
First Posted : June 5, 2008
Last Update Posted : January 12, 2009
Information provided by:

Brief Summary:
The current epidemiological study will be undertaken in GP's and specialized private doctors. In total, 85 general practitioners, orthopedics, rheumatologists and cardiologist will take part in the study. Data will be collected for 850 patients who visit their physician for medical conditions that require the use of acetylsalicylic acid and/or NSAIDS. The first 10 consecutive patients who visit their GP/orthopedic/rheumatologist/cardiologists and are currently receiving acetylsalicylic acid and/or NSAIDS will be included in the study.

Condition or disease
Upper-GI Symptoms

Layout table for study information
Study Type : Observational
Estimated Enrollment : 850 participants
Observational Model: Case-Only
Time Perspective: Cross-Sectional
Official Title: Upper GI Symptoms In Patients Receiving Acetylsalicylic Acid/NSAIDs - NSAIDs Wave 2
Study Start Date : March 2008
Actual Study Completion Date : December 2008

Primary care

Primary Outcome Measures :
  1. Frequency (%) of patients in the Greek Primary Practice, presenting Upper GI Symptoms while receiving NSAIDS treatment with/without gastroprotective measures. [ Time Frame: Single visit / once ]

Secondary Outcome Measures :
  1. The nature of upper GI symptoms (Dyspepsia and GERD) experienced by patients receiving acetylsalicylic acid and / or NSAIDS treatment [ Time Frame: single visit / once ]
  2. To determine the main indications for acetylsalicylic acid and or NSAIDS prescription among GPs and specialized private doctors in Greece. [ Time Frame: single visit / once ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Primary care

Inclusion Criteria:

  • Acetylsalicylic acid/NSAIDS intake for at least 5 days of a week during the past month before the patient's visit to the clinician

Exclusion Criteria:

  • Patients who are not willing to sign of the Informed Consent Form

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00691743

Layout table for location information
Research Site
Agrinio, Greece
Research Site
Alexandroupoli, Greece
Research Site
Argostoli, Greece
Research Site
Athens, Greece
Research Site
Chalkida, Greece
Research Site
Drama, Greece
Research Site
Heraklion, Greece
Research Site
Ioannina, Greece
Research Site
Kalamata, Greece
Research Site
Kallikratia, Greece
Research Site
Katerini, Greece
Research Site
Kiato, Greece
Research Site
Komotini, Greece
Research Site
Korinthos, Greece
Research Site
Kozani, Greece
Research Site
Lamia, Greece
Research Site
Larisa, Greece
Research Site
Patra, Greece
Research Site
Peireous, Greece
Research Site
Pirgos, Greece
Research Site
Preveza, Greece
Research Site
Rethimnon, Greece
Research Site
Serres, Greece
Research Site
Thessaloniki, Greece
Research Site
Tripoli, Greece
Research Site
Volos, Greece
Research Site
Xania, Greece
Sponsors and Collaborators
Layout table for investigator information
Principal Investigator: Rokkas Theodoros, MD Errikos Ntinan Hospital, Athens, Greece
Layout table for additonal information
Responsible Party: Pontikis Panagiotis, MD, Medical Department Director, AstraZeneca Greece Identifier: NCT00691743    
Other Study ID Numbers: NIS-GGR-DUM-2008/1
First Posted: June 5, 2008    Key Record Dates
Last Update Posted: January 12, 2009
Last Verified: January 2009
Keywords provided by AstraZeneca:
Upper GI Symptoms
Additional relevant MeSH terms:
Layout table for MeSH terms
Gastrointestinal Diseases
Signs and Symptoms, Digestive
Digestive System Diseases
Signs and Symptoms